Table of Contents
Advances in Pharmaceutics
Volume 2014 (2014), Article ID 435963, 10 pages
http://dx.doi.org/10.1155/2014/435963
Research Article

In Vitro Characterization of Six Month Dosage Forms for a GnRH Antagonist

1Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA
2Murty Pharmaceuticals, 518 Codell Drive, Lexington, KY 40509, USA
3Evonik, 750 Lakeshore Parkway, Birmingham, AL 35211, USA
4University of Kentucky College of Pharmacy, Lexington, KY 40536, USA

Received 4 April 2014; Accepted 28 May 2014; Published 15 July 2014

Academic Editor: Maria Cristina Bonferoni

Copyright © 2014 Susan D’Souza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Xuan, Y. Lin, J. Huang et al., “Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats,” Peptides, vol. 46, pp. 172–179, 2013. View at Google Scholar
  2. J. He, M. Feng, X. Zhou et al., “Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer,” International Journal of Pharmaceutics, vol. 416, no. 1, pp. 69–76, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Sun, S. Zhou, W. Wang, X. Li, J. Wang, and J. Weng, “Preparation and characterization of porous biodegradable microspheres used for controlled protein delivery,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 345, no. 1-3, pp. 173–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. H. K. Kim and T. G. Park, “Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-lactic-co-glycolic acid) microspheres: morphological effect on protein release,” Journal of Controlled Release, vol. 98, no. 1, pp. 115–125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. T. G. Park, H. Y. Lee, and Y. S. Nam, “A new preparation method for protein loaded poly(D,L-lactic-co-glycolic acid) microspheres and protein release mechanism study,” Journal of Controlled Release, vol. 55, no. 2-3, pp. 181–191, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. A. K. Banga and Y. W. Chien, “Systemic delivery of therapeutic peptides and proteins,” International Journal of Pharmaceutics, vol. 48, no. 1–3, pp. 15–50, 1988. View at Google Scholar · View at Scopus
  7. H. Okada and H. Toguchi, “Biodegradable microspheres in drug delivery,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 12, no. 1, pp. 1–99, 1995. View at Google Scholar · View at Scopus
  8. S. D’Souza, J. Faraj, and P. DeLuca, “Microsphere delivery of Risperidone as an alternative to combination therapy,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, pp. 631–639, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Garner, “Uses of GnRH agonists,” Journal of Obstetric, Gynecologic, and Neonatal Nursing, vol. 23, no. 7, pp. 563–570, 1994. View at Google Scholar · View at Scopus
  10. J. N. Pace, J. L. Miller, and L. I. Rose, “GnRH agonists: gonadorelin, leuprolide and nafarelin,” The American Family Physician, vol. 44, no. 5, pp. 1777–1782, 1991. View at Google Scholar · View at Scopus
  11. H. Lepor and N. D. Shore, “LHRH agonists for the treatment of prostate cancer: 2012,” Reviews in Urology, vol. 14, pp. 1–12, 2012. View at Google Scholar
  12. P. M. Conn and W. F. Crowley Jr., “Gonadotropin-releasing hormone and its analogs,” Annual Review of Medicine, vol. 45, pp. 391–405, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Kienle and G. Lübben, “Efficacy and safety of leuprorelin acetate depot for prostate cancer,” Urologia Internationalis, vol. 56, no. 1, pp. 23–30, 1996. View at Google Scholar · View at Scopus
  14. A. B. Copperman and C. Benadiva, “Optimal usage of the GnRH antagonists: a review of the literature,” Reproductive Biology and Endocrinology, vol. 11, no. 1, article 20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. F. Huirne and C. B. Lambalk, “Gonadotropin-releasing-hormone-receptor antagonists,” The Lancet, vol. 358, no. 9295, pp. 1793–1803, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. G. F. Weinbauer and E. Nieschlag, “LH-RH antagonists: state of the art and future perspectives,” Recent Results in Cancer Research, vol. 124, pp. 113–136, 1992. View at Google Scholar · View at Scopus
  17. L. A. Kiesel, A. Rody, R. R. Greb, and A. Szilágyi, “Clinical use of GnRH analogues,” Clinical Endocrinology, vol. 56, no. 6, pp. 677–687, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. J. W. Kostanski, B. A. Dani, B. Schrier, and P. P. DeLuca, “Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats,” Pharmaceutical Research, vol. 17, no. 4, pp. 445–450, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Okada, “One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate,” Advanced Drug Delivery Reviews, vol. 28, no. 1, pp. 43–70, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Sharifi, L. D. Knoll, J. Smith, and E. Kramolowsky, “Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer,” Urology, vol. 51, no. 2, pp. 271–276, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. Gupta, K. P. Rao, K. P. R. Choudary, and S. Pratima, “Preformulation studies of biodegradable drug implants of meloxicam for orthopedic patient care,” Journal of Pharmaceutical Science and Technology, vol. 3, pp. 494–498, 2011. View at Google Scholar
  22. S. Takada, T. Kurokawa, K. Miyazaki, S. Iwasa, and Y. Ogawa, “Utilization of an amorphous form of a water-soluble GPIIb/IIIa antagonist for controlled release from biodegradable microspheres,” Pharmaceutical Research, vol. 14, no. 9, pp. 1146–1150, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Ramstack, G. P. Grandolfi, E. Mannaert, P. D'Hoore, and R. A. Lasser, “Risperdal Consta: Prolonged-Release Injectable Delivery of Risperidone using Medisorb Microsphere Technology,” Abstract AAPS, 2002.
  24. E. Comets, F. Mentré, F. Nimmerfall et al., “Nonparametric analysis of the absorption profile of octreotide in rabbits from long-acting release formulation OncoLAR,” Journal of Controlled Release, vol. 59, no. 2, pp. 197–205, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. G.-K. Zou, Y.-L. Song, W. Zhou et al., “Effects of local delivery of bFGF from PLGA microspheres on osseointegration around implants in diabetic rats,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 114, no. 3, pp. 284–289, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. L. C. Amann, M. J. Gandal, R. Lin, Y. Liang, and S. J. Siegel, “in vitro-in vivo correlations of scalable plga-risperidone implants for the treatment of schizophrenia,” Pharmaceutical Research, vol. 27, no. 8, pp. 1730–1737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. U. Seju, A. Kumar, and K. K. Sawant, “Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies,” Acta Biomaterialia, vol. 7, no. 12, pp. 4169–4176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D'Souza, J. A. Faraj, S. Giovagnoli, and P. P. DeLuca, “Development of risperidone PLGA microspheres,” Journal of Drug Delivery, vol. 2014, Article ID 620464, 11 pages, 2014. View at Publisher · View at Google Scholar
  29. J. Braunecker, M. Baba, G. E. Milroy, and R. E. Cameron, “The effects of molecular weight and porosity on the degradation and drug release from polyglycolide,” International Journal of Pharmaceutics, vol. 282, no. 1-2, pp. 19–34, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. T. G. Park, “Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition,” Biomaterials, vol. 16, no. 15, pp. 1123–1130, 1995. View at Publisher · View at Google Scholar · View at Scopus
  31. E. O. Akala, P. Wiriyacoonkasem, and G. Pan, “Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres,” Drug Development and Industrial Pharmacy, vol. 37, no. 6, pp. 673–684, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. D'Souza, J. A. Faraj, S. Giovagnoli, and P. P. DeLuca, “Preparation, characterization and in vivo evaluation of Olanzapine Poly(D, L-lactide-co-glycolide) (PLGA) microspheres,” Journal of Pharmaceutics, vol. 2013, Article ID 831381, 9 pages, 2013. View at Publisher · View at Google Scholar
  33. J. W. Kostanski, B. C. Thanoo, and P. P. DeLuca, “Preparation, characterization, and in vitro evaluation of 1- and 4-month controlled release orntide PLA and PLGA microspheres,” Pharmaceutical Development and Technology, vol. 5, no. 4, pp. 585–596, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Ploussard and P. Mongiat-Artus, “Triptorelin in the management of prostate cancer,” Future Oncology, vol. 9, no. 1, pp. 93–102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. C.-C. Kao, Y.-H. Chang, T. Wu et al., “Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer,” Journal of the Chinese Medical Association, vol. 75, no. 6, pp. 255–261, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Fontana, M. Mari, A. Martinelli et al., “3-Month formulation of goserelin acetate (“Zoladex” 10.8-mg Depot) in advanced prostate cancer: results from an Italian, open, multicenter trial,” Urologia Internationalis, vol. 70, no. 4, pp. 316–320, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. E. David Crawford and J. M. Phillips, “Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort,” Cancer Management and Research, vol. 3, no. 1, pp. 201–209, 2011. View at Google Scholar · View at Scopus
  38. U. W. Tunn, “A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients,” BMC Urology, vol. 11, article 15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Spitz, J. M. Young, L. Larsen, C. Mattia-Goldberg, J. Donnelly, and K. Chwalisz, “Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 15, no. 1, pp. 93–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. U. W. Tunn, D. Gruca, and P. Bacher, “Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation,” Clinical Interventions in Aging, vol. 8, pp. 457–464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. W. Kostanski and P. P. DeLuca, “A novel in vitro release technique for peptide containing biodegradable microspheres,” AAPS PharmSciTech, vol. 1, no. 1, article E4, 2000. View at Google Scholar · View at Scopus
  42. S. D'Souza, J. A. Faraj, S. Giovagnoli, and P. P. DeLuca, “IVIVC from long acting olanzapine microspheres,” International Journal of Biomaterials, vol. 2014, Article ID 407065, 11 pages, 2014. View at Publisher · View at Google Scholar
  43. G. Reich, “Use of DSC to study the degradation behavior of PLA and PLGA microparticles,” Drug Development and Industrial Pharmacy, vol. 23, no. 12, pp. 1177–1189, 1997. View at Google Scholar · View at Scopus
  44. M. Shameem, H. Lee, and P. P. DeLuca, “A short-term (accelerated release) approach to evaluate peptide release from PLGA depot formulations,” AAPS PharmSci, vol. 1, no. 3, article 7, 1999. View at Google Scholar · View at Scopus
  45. S. D'Souza, J. A. Faraj, R. Dorati, and P. P. DeLuca, “A short term quality control tool for biodegradable microspheres,” AAPS PharmSciTech, vol. 15, no. 3, pp. 530–541, 2014. View at Google Scholar
  46. S. S. D’Souza, J. A. Faraj, and P. P. DeLuca, “A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres,” AAPS PharmSciTech, vol. 6, no. 4, article 70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Higuchi, “Rate of release of medicaments from ointment bases containing drugs in suspension,” Journal of pharmaceutical sciences, vol. 50, pp. 874–875, 1961. View at Google Scholar · View at Scopus